KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Convertible Debt: 2013-2022

Historic Convertible Debt for Supernus Pharmaceuticals (SUPN) over the last 8 years, with Mar 2022 value amounting to $400.4 million.

  • Supernus Pharmaceuticals' Convertible Debt rose 9.38% to $400.4 million in Q1 2022 from the same period last year, while for Mar 2022 it was $400.4 million, marking a year-over-year increase of 9.38%. This contributed to the annual value of $379.3 million for FY2021, which is 4.84% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Convertible Debt of $400.4 million as of Q1 2022, which was up 5.57% from $379.3 million recorded in Q4 2021.
  • Over the past 5 years, Supernus Pharmaceuticals' Convertible Debt peaked at $400.4 million during Q1 2022, and registered a low of $318.2 million during Q1 2018.
  • Its 3-year average for Convertible Debt is $368.1 million, with a median of $366.0 million in 2021.
  • Data for Supernus Pharmaceuticals' Convertible Debt shows a peak YoY surged of 21,769.57% (in 2018) over the last 5 years.
  • Supernus Pharmaceuticals' Convertible Debt (Quarterly) stood at $329.5 million in 2018, then rose by 4.77% to $345.2 million in 2019, then climbed by 4.80% to $361.8 million in 2020, then grew by 4.84% to $379.3 million in 2021, then climbed by 9.38% to $400.4 million in 2022.
  • Its Convertible Debt stands at $400.4 million for Q1 2022, versus $379.3 million for Q4 2021 and $374.8 million for Q3 2021.